Update on Licensing Progenza in Japan
Sydney, July 3, 2018 AEST (ABN Newswire) - Regeneus Ltd (
ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated. Part of this delay is due to there being several interested parties in active discussions for licensing Progenza.
As announced on Friday, the company has entered into an R&D loan facility agreement and has drawn down $1 million. The funds will be utilised in operational expenditure.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
